Low-calcium dialysate improves mineral metabolism in hemodialysis patients

Clinical Nephrology

Volumn 67, Issue 1, 2007, Pages 20-24

  Fujimori, A ^a   Yorifuji, M ^a   Sakai, M ^a   Oyama, M ^a   Nakao, N ^b   Tokuyama, M ^b   Fukagawa, M ^c  

^a Konan Hospital   (Japan)

^b Konan Hospital Foundation Rokko Island Hospital   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dialysate calcium; Serum calcium; Serum phosphorus; Whole PTH

Indexed keywords

22 OXACALCITRIOL; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; FALECALCITRIOL; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; VITAMIN D DERIVATIVE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DIALYSATE LEVEL; DRUG DOSE INCREASE; DRUG USE; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PRIMARY PREVENTION; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

EID: 33847327503     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP67020     Document Type: Article

References (17)

1. Akizawa T, Fukagawa M, Koshikawa S, Kurokawa K. Recent progress in management of secondary hyperparathyroidism of chronic renal failure. Curr Opin Nephrol Hypertens. 1993; 2: 558-565.
2. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999; 33: 694-701.
3. 2D levels in renal disease. Kidney Int. 1983; 24: 104-109.
4. Fernandez E, Borras M, Pais B, Montoliu J. Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol. 1995; 6: 132-135.
5. Hamano T, Oseto S, Fujii N, Ito T, Katayama M, Horio M, Imai E, Hori M. Impact of lowering dialysate calcium concentration on bone remodeling in hemodialysis patients. Bone. 2005; 36: 909-916.
6. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA. 1993; 80: 201-204.
7. Igarashi Y, Mochizuki Y, Miura T, Ohashi T, Sasagawa K, Katayama K, Inaba N, Matsuzaki. Evaluation of a novel immunoassay for serum tartrate-resistant acid phosphatase type 5b activity in hormone replacement therapy. Bone. 2003; 32: S179.
8. 3 on primary antibody formation in mice. Immunopharmacology. 1985; 9: 141-146.
9. Mason RS, Lissner D, Wilkinson M, Posen S. Vitamin D metabolites and their relationship to azotemic osteodystrophy. Clin Endocrinol (Oxf). 1980; 13: 375-385.
10. Mawer EB, Backhouse J, Taylor CM, Lumb GA, Stanbury SW. Failure of formation of 1.25 dihydroxycholechalciferol in chronic renal insufficiency. Lancet. 1973; 1: 626-628.
11. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant. 2002; 17: 1643-1648.
12. National Kidney Foundation. K/DOQI Clinical Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003; 41 (Suppl 3): S1-S202.
13. Sanchez Perales MC, Garcia Cortes MJ, Borrego FJ, Fernandez Martinez S, Borrego J, Perez del Barrio P, Liebana A, Perez Banasco V. Hemodialysis with 1.25 mmol/l of calcium in relative hypoparathyroidism: long-term effects on bone mass. Nefrologia. 2000; 20: 254-261.
14. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. 1989; 36: 897-903.
15. Tokumoto A. Bone histological validation of the Scantibodies 1-84 PTH (CAP) assay and the 1-84 PTH/large C terminal fragment ratio. J Am Soc Nephrol. 2003; 14: 688A.
16. Wada A, Kitaoka T, Nakai S, Shinzato T, Nagura Y, Kikuchi K, Masakane I, Shinoda T, Yunazaki C, Sakai R, Marubayasi S, Morita O, Iseki K, Usami T, Kimata N, Suzuki K, Tabei K, Fushimi K, Miwa N, Yanai M, Wakai T, Akiba T. An overview of dialysis treatment in Japan (as of Dec. 31, 2003). J Japan Soc Dial Treat. 2005; 38: 1-16.
17. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisani RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.